Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Johnson and Johnson
Harvard Business School
Merck
Express Scripts

Last Updated: May 19, 2022

CLINICAL TRIALS PROFILE FOR RECLAST


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Reclast

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00171964 ↗ Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone Lesions Completed Novartis Pharmaceuticals Phase 4 2002-05-01 It is the aim of this multicentric clinical study to assess the efficacy and tolerability of zoledronic acid in combination with radiotherapy in patients with advanced osteolytic bone lesions in terms of the reduction of pain and analgesic consumption.
NCT00305695 ↗ Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries Completed National Cancer Institute (NCI) Phase 2 2005-11-28 This randomized phase II trial is studying zoledronate to see how well it works compared to observation in maintaining bone mineral density in patients who are undergoing surgery to remove both ovaries. Zoledronate may prevent bone loss in patients who are undergoing surgery to remove the ovaries.
NCT00305695 ↗ Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries Completed Gynecologic Oncology Group Phase 2 2005-11-28 This randomized phase II trial is studying zoledronate to see how well it works compared to observation in maintaining bone mineral density in patients who are undergoing surgery to remove both ovaries. Zoledronate may prevent bone loss in patients who are undergoing surgery to remove the ovaries.
NCT00439647 ↗ Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis Completed Novartis Pharmaceuticals Phase 3 2006-12-01 This study will investigate if the drug zoledronic acid given once yearly is safe and has beneficial effects in treating osteoporosis by reducing bone loss and fractures in men with osteoporosis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Reclast

Condition Name

Condition Name for Reclast
Intervention Trials
Osteoporosis 11
Bone Loss 5
Osteoporosis, Postmenopausal 3
Paget's Disease of the Bone 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Reclast
Intervention Trials
Osteoporosis 17
Osteoporosis, Postmenopausal 5
Osteoporotic Fractures 3
Bone Diseases, Metabolic 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Reclast

Trials by Country

Trials by Country for Reclast
Location Trials
United States 89
Canada 7
Spain 5
Australia 5
Belgium 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Reclast
Location Trials
Pennsylvania 8
New York 5
Michigan 4
Massachusetts 4
California 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Reclast

Clinical Trial Phase

Clinical Trial Phase for Reclast
Clinical Trial Phase Trials
Phase 4 14
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Reclast
Clinical Trial Phase Trials
Completed 14
Recruiting 7
Active, not recruiting 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Reclast

Sponsor Name

Sponsor Name for Reclast
Sponsor Trials
National Institute on Aging (NIA) 5
Novartis Pharmaceuticals 5
National Institutes of Health (NIH) 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Reclast
Sponsor Trials
Other 31
NIH 12
Industry 10
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Medtronic
Colorcon
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.